Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Berger

Showing results (61-70 of 239) with videos related to

Pageof 24
Sort By:
American Heart Journal|February 3, 2009
Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trialHerbert D Aronow, Steven R Steinhubl, Danielle M Brennan, et al.
Journal of Thrombosis and Thrombolysis|March 4, 2005
Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry studyDeepak Talreja, Dieter Lubbe, James L Orford, et al.
Atherosclerosis|November 6, 2002
Lack of association between plasma homocysteine and angiographic coronary artery disease in the era of fortification of cereal grain flour with folic acidEmmanouil S Brilakis, Joseph P McConnell, Karla V Ballman, et al.
The American Journal of Cardiology|November 26, 2008
Emergency pretreatment for contrast allergy before direct percutaneous coronary intervention for ST-elevation myocardial infarctionC Randall Hubbard, James C Blankenship, Thomas D Scott, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 9, 2014
Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trialsSalvatore Cassese, Robert A Byrne, Karl-Ludwig Laugwitz, et al.
Journal of Interventional Cardiology|February 6, 2013
Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?Peter B Berger, Judson B Williams, Vic Hasselblad, et al.
Circulation|May 7, 2003
Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS)Mandeep Singh, Uri Rosenschein, Kalon K L Ho, et al.
The American Journal of Cardiology|September 3, 2004
Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat interventionJacqueline Saw, Eric J Topol, Steven R Steinhubl, et al.
Journal of the American College of Cardiology|February 19, 2008
Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end pointGjin Ndrepepa, Peter B Berger, Julinda Mehilli, et al.
Circulation|October 29, 2003
Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery diseasePaul Sorajja, Steve R Ommen, Rick A Nishimura, et al.
Pageof 24

Showing results (61-70 of 239) with videos related to

Sort By:
Pageof 24
American Heart Journal|February 3, 2009
Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trialHerbert D Aronow, Steven R Steinhubl, Danielle M Brennan, et al.
Journal of Thrombosis and Thrombolysis|March 4, 2005
Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry studyDeepak Talreja, Dieter Lubbe, James L Orford, et al.
Atherosclerosis|November 6, 2002
Lack of association between plasma homocysteine and angiographic coronary artery disease in the era of fortification of cereal grain flour with folic acidEmmanouil S Brilakis, Joseph P McConnell, Karla V Ballman, et al.
The American Journal of Cardiology|November 26, 2008
Emergency pretreatment for contrast allergy before direct percutaneous coronary intervention for ST-elevation myocardial infarctionC Randall Hubbard, James C Blankenship, Thomas D Scott, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 9, 2014
Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trialsSalvatore Cassese, Robert A Byrne, Karl-Ludwig Laugwitz, et al.
Journal of Interventional Cardiology|February 6, 2013
Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?Peter B Berger, Judson B Williams, Vic Hasselblad, et al.
Circulation|May 7, 2003
Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS)Mandeep Singh, Uri Rosenschein, Kalon K L Ho, et al.
The American Journal of Cardiology|September 3, 2004
Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat interventionJacqueline Saw, Eric J Topol, Steven R Steinhubl, et al.
Journal of the American College of Cardiology|February 19, 2008
Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end pointGjin Ndrepepa, Peter B Berger, Julinda Mehilli, et al.
Circulation|October 29, 2003
Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery diseasePaul Sorajja, Steve R Ommen, Rick A Nishimura, et al.
Pageof 24